Acomplia (rimonabant), a promising new drug for obesity, smoking cessation, and high cholesterol

November 2004

Researchers are excited about Acomplia (rimonabant), a promising new drug for obesity, smoking cessation, and high cholesterol.

The lay press has picked up on this too-good-to-be-true drug, and people are asking about it.

It's the first in a new class...called selective cannabinoid type 1 (CB1) blockers.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

New treatments are being used for skin infections
The flu vaccine shortage will put new emphasis on FluMist and antivirals
Anticoagulants stop warfarin prior to surgery or other invasive procedures
Anticoagulants The new oral anticoagulant Exanta (ximelagatran) won't be replacing warfarin any time soon
Asthma single IM dose of methylprednisolone instead of oral steroids
NSAIDs Lots of patients are asking about alternatives to Vioxx
Pediatrics Mild croup will be treated more frequently with dexamethasone
Pediatrics Nuvo lotion for head lice
Osteoporosis Do carbonated beverages cause bone loss
Women's Health Diflucan once a WEEK to PREVENT recurrent vaginal yeast infections
Supplements if prickly pear cactus can prevent hangovers
Neurology & Pain Parcopa, a new carbidopa/levodopa tablet that dissolves on the tongue
Neurology & Pain Acomplia (rimonabant), a promising new drug for obesity, smoking cessation, and high cholesterol
Gastroenterology Celiac disease (sprue) is more common than previously thought
Cardiology risk of potentially fatal arrhythmias with erythromycin